The Global nLPHL One Working Group (GLOW) is an international, multidisciplinary collaborative research group that aims to improve the diagnosis and treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
We serve as a coordinated research hub to drive NLPHL discovery across the age continuum.
NLPHL is distinct from other Hodgkin lymphomas.
There is no standard of care approach for the treatment of NLPHL.
Survival rates for patients with NLPHL are high, but the cumulative effects of treatment(s) over the lifecourse can be detrimental.
No formal evaluation of patients' values, preferences, and priorities has been conducted in regards to NLPHL treatment.
No frontline Hodgkin lymphoma trial anywhere in the world currently includes patients with NLPHL.
There is uncertainty regarding how to best classify NLPHL.
Scientific understanding of NLPHL lags behind more common cancers.
Many current gaps in knowledge about NLPHL and optimal treatment strategies can be addressed via global collaboration.
We are learning from past research and experience, so we:
The Global nLPHL One Working Group is committed to improving outcomes for all patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma.
Interested in joining GLOW? Complete our Tell Us About You form!